California-based start-up Bitterroot Bio has launched with a focus on developing immunotherapies for cardiovascular diseases, following a successful $145m series A funding round. The company was founded by Irving Weissman and Nicholas Leeper from the Stanford University School of Medicine in 2021 and is focused on cardio-immunology. Its lead programme, BRB-002 targets CD47/SIRPα pathways underlying vascular inflammation and atherosclerosis. Although anti-CD47 approaches have been effective in mice trials, they have yet to be tested in humans. Bitterroot’s leadership team includes CEO Pavan Cheruvu who previously worked at Roivant Sciences and Sio Gene Therapies; CMO Crag Basson; and co-founders Leeper and Weissman.
Keywords: California, start-up, Bitterroot Bio, immunotherapies, cardiovascular diseases
Bitterroot Bio's launch marks an exciting development in the field of cardio-immunology as it aims to develop novel therapies for heart conditions through targeting CD47/SIRPα pathways which are responsible for vascular inflammation and atherosclerosis. This project could provide significant benefits given that many people suffer from these conditions worldwide. Furthermore, the success of this venture could pave the way for similar developments